Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Subscribe To Our Newsletter & Stay Updated
